Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized, 2-treatment, 3-period, 3-sequence crossoverbioequivalence study comparing a combination tablet containing clopidogrel andenteric aspirin versus the simultaneous administration of separate formulations ofthese two drugs in healthy Chinese subjects under fed conditions

Next Previous
Trial Profile

An open-label, randomized, 2-treatment, 3-period, 3-sequence crossoverbioequivalence study comparing a combination tablet containing clopidogrel andenteric aspirin versus the simultaneous administration of separate formulations ofthese two drugs in healthy Chinese subjects under fed conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/clopidogrel (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sanofi China Investment

Most Recent Events

  • 24 Sep 2020 Primary endpoint has been met. (AUClast)
  • 24 Sep 2020 Primary endpoint has been met. (Cmax)
  • 24 Sep 2020 Primary endpoint has been met. (AUC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top